Tag Archives: primary angioplasty

DES con polímero bioabsorbible vs Bare Metal Stents en angioplastia primaria

DES with Bioresorbable Polymer vs. Bare Metal Stents in Primary PCI

DES with Bioresorbable Polymer vs. Bare Metal Stents in Primary PCI

Long after myocardial revascularization guidelines had established no medical reason justifies the use of bare metal stents (BMS), along comes this study to refresh the old trials comparing drug eluting vs bare metal stents in the context of primary PCI. The problem for many countries is that primary PCI obviously occurs in the context of

ACC 2019 | SAFARI: sorpresivamente, el acceso radial no ofrece ventajas en el infarto

ACC 2019 | SAFARI: Unexpectedly, Radial Approach Offers No Benefits In STEMI

This study was not able to show benefits in terms of mortality or bleeding when using radial vs. femoral approach in patients undergoing ST elevation myocardial Infarction. This small trial does not change things for “radialists” way past their learning curve who already feel confident with this technique. For them, there is no way back.

Stent directo vs angioplastia convencional y sus interacciones con la trombo-aspiración

Direct Stenting vs. Conventional Angioplasty and Their Interaction with Thrombus Aspiration

The rates of direct stenting are higher among patients randomized to thrombus aspiration. The rates of clinical events and myocardial reperfusion did not differ significantly between a direct stenting strategy vs. predilation and stenting, and no interaction was observed as regards thrombus aspiration. Several preliminary studies have emerged from the hypothesis that a direct stenting

MATRIX: Superioridad del acceso radial al año

ESC 2018 | MATRIX: 1-Year Superiority of Transradial Access

Transradial access should be the access of choice in patients with acute coronary syndrome, while bivalirudin has not shown any benefit for this population. The long-term follow-up from the MATRIX (Minimizing Adverse Hemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox) trial confirms the results at 30 days: transradial access is here to stay

TRANSIENT trial: ¿Cuál es el mejor momento para revascularizar un SCA con elevación transitoria del ST?

EuroPCR 2018 | TRANSIENT trial: What is the best timing for TRANSIENT STEMI revascularization?

The objective of this study was to determine the best time to revascularize a patient who is undergoing an acute coronary syndrome (ACS) with transient ST segment elevation. This population hovers around 15% of STEMI patients. The question is whether to reduce infarction area (or potential reinfarction) with an immediate intervention, or to delay intervention

OxAMI-PICSO: oclusión del seno coronario: mejorar la función microvascular y reducir el tamaño del infarto

EuroPCR 2018 | OxAMI-PICSO: Coronary Sinus Occlusion, Improving Microvascular Function and Reducing Infarct Size

The index of microcirculatory resistance might guide therapy and controlled intermittent coronary sinus occlusions, improve microvascular function, and reduce infarct size. This study included patients with prior ST-segment elevation myocardial infarction treated with primary angioplasty. Researchers measured the index of microcirculatory resistance before stenting and intermittent coronary sinus occlusion was used if the result was

SEMPER-FI: el resurgimiento del balón de contrapulsación

EuroPCR 2018 | SEMPER-FI: The Reemergence of the Intra-Aortic Balloon Counterpulsation

The intra-aortic balloon counterpulsation affects patients through a combination of coronary flow improvement and afterload reduction. It has been the subject matter of several studies, but its benefit as mechanical support has not been proven. This work aims to prove the benefits of balloon counterpulsation in patients with ST-segment elevation acute myocardial infarction who, after

EuroPCR 2018 | LEADERS FREE: angioplastias complejas en pacientes con alto riesgo de sangrado

EuroPCR 2018 | LEADERS FREE: Complex Angioplasty in Patients with High Risk for Bleeding

The LEADERS FREE study showed that a biolimus A9-coated polymer-free stent was superior to a conventional stent in terms of safety and efficacy in patients who received dual antiplatelet therapy for only a month due to their high risk for bleeding. In this substudy, researchers analyzed 667 patients enrolled in the original LEADERS FREE trial who met certain requirements

Registro Sueco con stent SYNERGY: por primera vez stent probado en angioplastia primaria

EuroPCR 2018 | Swedish Registry on the SYNERGY DES: tested in primary PCI for the first time

The study included 36292 consecutive patients undergoing acute myocardial infarction receiving PCI with the new generation stent SYNERGY (thin struts, bioresorbable polymer and everolimus eluting); 39.7% presented ST elevation MI. Kaplan-Meier curves at 2 years of patients receiving the SYNERGY vs patients receiving other drug eluting stents resulted very similar for thrombosis (0,69% vs 0,81%,


Elderly Patients with ACS: Clopidogrel or Reduced-Dose Prasugrel?

Elderly patients are at elevated risk of both ischemic and bleeding complications after an acute coronary syndrome (ACS), and display higher platelet reactivity under clopidogrel when compared to younger patients. A 5-mg dose of prasugrel would provide more predictable platelet inhibition than clopidogrel in elderly populations, without the risk of bleeding entailed by the full